Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.79 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29505763 | 1.00 | POLB (0.79) | POLBNPC1RAB9ADDAH1CHRM1 | |
| Hydrochloric Acid SCHEMBL8327038 | 0.98 | POLB (0.77) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL1884524 | 0.95 | POLB (0.83) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL4705680 | 0.93 | POLB (0.80) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL4704495 | 0.93 | POLB (0.80) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL10766533 | 0.93 | POLB (0.80) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL524002 | 0.89 | POLB (0.72) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL29620366 | 0.89 | POLB (0.72) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL7854448 | 0.89 | POLB (0.92) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL7006523 | 0.89 | POLB (1.00) | POLBNPC1RAB9ADDAH1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0226016-A1 | Process for inhibiting hydrogen-induced corrosion of metallic materials | BAYER AG (DE) | 1987-06-24 | — | — | EP | claimed |
| US-4000079-A | ANTIFREEZE ADDITIVES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-12-28 | — | — | US | claimed |
| EP-3364967-B1 | FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-3365339-B1 | NOVEL FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2025-07-16 | — | — | EP | disclosed |
| US-20220363675-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2022-11-17 | — | — | US | disclosed |
| EP-3212201-B1 | NUCLEOSIDE KINASE INHIBITORS | BCI PHARMA (FR) | 2022-10-19 | — | — | EP | disclosed |
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | B.C.I. PHARMA (BE) | 2022-02-01 | — | — | US | disclosed |
| US-10738039-B2 | Metal plating compositions | ROHM AND HAAS ELECTRONIC MATERIALS LLC (US) | 2020-08-11 | — | — | US | disclosed |
| US-10632125-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2020-04-28 | — | — | US | disclosed |
| EP-3288991-B1 | REACTION PRODUCTS OF DIAMINES WITH REACTION PRODUCTS OF MONOAMINES AND BISANHYDRIDES AS ADDITIVES FOR ELECTROPLATING BATHS | ROHM & HAAS ELECT MAT (US) | 2020-03-18 | — | — | EP | disclosed |
| CN-107454908-B | Reaction products of diamines with reaction products of monoamines and diacids as plating bath additives | 罗门哈斯电子材料有限责任公司 | 2020-02-14 | — | — | CN | disclosed |
| EP-0787711-A2 | Process for the preparation of alpha,beta-unsaturated carboxylic acids | F. HOFFMANN-LA ROCHE AG (CH) | 1997-08-06 | — | — | EP | disclosed |
| EP-0226016-A1 | Process for inhibiting hydrogen-induced corrosion of metallic materials | BAYER AG (DE) | 1987-06-24 | — | — | EP | disclosed |
| US-4434174-A | Treating cardiovascular diseases with N-(3-phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines | BERLEX LABORATORIES, INC. (US) | 1984-02-28 | — | — | US | disclosed |
| US-4296256-A | 2-Decarboxy-2-hydroxymethyl-19-keto-PG compounds | THE UPJOHN COMPANY (US) | 1981-10-20 | — | — | US | disclosed |
| US-4235838-A | IN OIL AND GAS WELLS | PETROLITE CORPORATION (US) | 1980-11-25 | — | — | US | disclosed |
| US-4104194-A | 1,2-FUSED 5- OR 6-MEMBERED 1,3-DINITROGEN HETEROCYCLIC COMPOUNDS AS ANTICORROSION AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1978-08-01 | — | — | US | disclosed |
| US-4048174-A | ANTI-CORROSION AGENTS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-09-13 | — | — | US | disclosed |
| US-4000079-A | ANTIFREEZE ADDITIVES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-12-28 | — | — | US | disclosed |
| US-3972890-A | ACID CATALYST | BAYER AKTIENGESELLSCHAFT (DT) | 1976-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | ADK, TNNI3K, TNK2 | POLB 2593/4885NPC1 2425/4885RAB9A 2414/4885 |
| US-10738039-B2 | Metal plating compositions | MAOA, GAP43, MAOB | POLB 23/4885NPC1 4763/4885RAB9A 759/4885 |
| US-10632125-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | MTHFD1, MTHFD2, TPMT | POLB 1116/4885NPC1 903/4885RAB9A 2672/4885 |
| US-20220363675-A1 | Novel Ferroportin Inhibitors | HAMP, SLC40A1, HMOX1 | POLB 4246/4885NPC1 445/4885RAB9A 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.